These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37765060)

  • 1. Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases.
    Smukowska-Gorynia A; Gościniak W; Woźniak P; Iwańczyk S; Jaxa-Kwiatkowska K; Sławek-Szmyt S; Janus M; Paluszkiewicz J; Mularek-Kubzdela T
    Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for pulmonary arterial hypertension.
    Parikh V; Bhardwaj A; Nair A
    J Thorac Dis; 2019 Sep; 11(Suppl 14):S1767-S1781. PubMed ID: 31632754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.
    Cansu DÜ; Korkmaz C
    Clin Rheumatol; 2023 Oct; 42(10):2601-2610. PubMed ID: 36396789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
    Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.
    Raina A; Benza RL; Farber HW
    Pulm Circ; 2017; 7(3):741-746. PubMed ID: 28671485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
    Distler O; Ofner C; Huscher D; Jordan S; Ulrich S; Stähler G; Grünig E; Held M; Ghofrani HA; Claussen M; Lange TJ; Klose H; Rosenkranz S; Vonk-Noordegraaf A; Vizza CD; Delcroix M; Opitz C; Pausch C; Scelsi L; Neurohr C; Olsson KM; Coghlan JG; Halank M; Skowasch D; Behr J; Milger K; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Wilkens H; Pittrow D; Hoeper MM; Ewert R
    Rheumatology (Oxford); 2024 Apr; 63(4):1139-1146. PubMed ID: 37462520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on pulmonary arterial hypertension pharmacotherapy.
    Velayati A; Valerio MG; Shen M; Tariq S; Lanier GM; Aronow WS
    Postgrad Med; 2016 Jun; 128(5):460-73. PubMed ID: 27232660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
    Sargent T; Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Cloutier M; Lefebvre P
    Adv Ther; 2023 Nov; 40(11):5037-5054. PubMed ID: 37728697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
    Erdogan M; Esatoglu SN; Kilickiran Avci B; Hatemi G
    Intern Emerg Med; 2024 Apr; 19(3):731-743. PubMed ID: 38378970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 14. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
    Gratsianskaya SE; Valieva ZS; Martynyuk TV
    Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pulmonary arterial hypertension in connective tissue disease.
    Grünig E
    Drugs; 2012 May; 72(8):1039-56. PubMed ID: 22621693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.
    Buckley MS; Berry AJ; Kazem NH; Patel SA; Librodo PA
    Core Evid; 2014; 9():71-80. PubMed ID: 25018685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease.
    Nakanishi N; ;
    Allergol Int; 2011 Dec; 60(4):419-24. PubMed ID: 22015568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
    Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
    Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.